Glycan Targets of Serum IgG and IgM Antibodies
AssigneeRegents of the University of Minnesota
InventorChristopher BURLAK
Life of this patent
Estimating the term…
Abstract
Provided herein are genetically modified porcine cells comprising a reduced or eliminated level of β1,3-N-acetylglucosaminyltransferase 5 (B3gnt5) activity as compared to a normal porcine cell, and methods of improving a rejection related symptom by transplanting porcine cells, tissues or organs to a subject in need thereof.
Claims25
A genetically modified porcine cell comprising a reduced level of β1,3-N-acetylglucosaminyltransferase 5 activity as compared to a normal porcine cell.
A genetically modified porcine cell comprising a biologically inactive or deleted β1,3-N-acetylglucosaminyltransferase 5 (B3gnt5) gene.
A genetically modified porcine cell comprising a reduced level of Lacto-N-neotetraose (LNnT) glycan (Galb1-4GlcNAcb1-3Galb1) on its cell surface as compared to a normal porcine cell.
A method of improving a rejection related symptom in a human subject comprising transplanting
- (a) porcine transplant material having reduced levels of β1,3-N-acetylglucosaminyltransferase 5 activity;
- (b) porcine transplant material having reduced levels of Lacto-N-neotetraose (LNnT) glycan (Galb1-4GlcNAcb1-3Galb1) on cell surfaces;
- or
- (c) porcine transplant material having reduced levels of Lacto-N-neotetraose (LNnT) epitope (Galb1-4GlcNAcb1-3Galb1);
- into a human subject in need of a transplant, wherein a rejection related symptom is improved as compared to when porcine transplant material from a wild-type pig is transplanted into a human subject.
12-13. (canceled)
Dependencies are inferred from the claim text.